Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants

Thrombosis Research

Volumn 136, Issue 3, 2015, Pages 582-589

  Posch, Florian ^a   Königsbrügge, Oliver ^a   Zielinski, Christoph ^a   Pabinger, Ingrid ^a   Ay, Cihan ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Cancer; Low molecular weight heparin; Network meta analysis; Oral anticoagulants; Treatment; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DIRECT ACTING ORAL ANTICOAGULANT; LOW MOLECULAR WEIGHT HEPARIN; UNCLASSIFIED DRUG; VITAMIN K GROUP;

ARTICLE; BLEEDING; CANCER PATIENT; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK FACTOR; RISK REDUCTION; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; COMORBIDITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EPIDEMIOLOGY; EVIDENCE BASED MEDICINE; FEMALE; HEMORRHAGE; INCIDENCE; MALE; NEOPLASMS; RISK ASSESSMENT; TREATMENT OUTCOME;

ANTICOAGULANTS; CAUSALITY; COMORBIDITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE-BASED MEDICINE; FEMALE; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INCIDENCE; MALE; NEOPLASMS; RISK ASSESSMENT; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 84940435041     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.07.011     Document Type: Article

References (33)

1. A.A. Khorana, C.W. Francis, E. Culakova, N.M. Kuderer, and G.H. Lyman Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy J. Thromb. Haemost. 5 2007 632 634
2. P. Prandoni, A.W. Lensing, A. Piccioli, E. Bernardi, P. Simioni, B. Girolami, and et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis Blood 100 2002 3484 3488
3. G.H. Lyman, A.A. Khorana, N.M. Kuderer, A.Y. Lee, J.I. Arcelus, E.P. Balaban, and et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update J. Clin. Oncol. 31 2013 2189 2204
4. M. Carrier, C. Cameron, A. Delluc, L. Castellucci, A.A. Khorana, and A.Y. Lee Efficacy and Safety of Anticoagulant Therapy for the Treatment of Acute Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis Thromb. Res. 134 2014 1214 1219
5. M.N. Di Minno, W. Ageno, and F. Dentali Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism: comment J. Thromb. Haemost. 12 2014 2136 2138
6. G.H. Guyatt, E.A. Akl, M. Crowther, D.D. Gutterman, and H.J. Schuunemann Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 7S 47S
7. S.V. Konstantinides, A. Torbicki, G. Agnelli, N. Danchin, D. Fitzmaurice, N. Galie, and et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)Endorsed by the European Respiratory Society (ERS) Eur. Heart J. 35 2014 3033 3073
8. M. Mandala, A. Falanga, and F. Roila Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines Ann. Oncol. 22 Suppl. 6 2011 vi85 vi92
9. D. Farge, P. Debourdeau, M. Beckers, C. Baglin, R.M. Bauersachs, B. Brenner, and et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer J. Thromb. Haemost. 11 2013 56 70
10. R.D. Hull, G.F. Pineo, R. Brant, J. Liang, R. Cook, S. Solymoss, and et al. Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome Am. J. Med. 122 2009 (762-9 e3)
11. G. Agnelli, H.R. Buller, A. Cohen, M. Curto, A.S. Gallus, M. Johnson, and et al. Oral apixaban for the treatment of acute venous thromboembolism N. Engl. J. Med. 369 2013 799 808
12. H.R. Buller, H. Decousus, M.A. Grosso, M. Mercuri, S. Middeldorp, M.H. Prins, and et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism N. Engl. J. Med. 369 2013 1406 1415
13. M.H. Prins, A.W. Lensing, R. Bauersachs, B. van Bellen, H. Bounameaux, T.A. Brighton, and et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies Thromb. J. 11 2013 21
14. S. Schulman, A.K. Kakkar, S.Z. Goldhaber, S. Schellong, H. Eriksson, P. Mismetti, and et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis Circulation 129 2014 764 772
15. J. Beyer-Westendorf, and W. Ageno Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism Thromb. Haemost. 113 2014
16. T. van der Hulle, P.L. den Exter, J. Kooiman, J.J. van der Hoeven, M.V. Huisman, and F.A. Klok Meta-analysis of the efficacy and safety of new oral anticoagulants in patients with cancer-associated acute venous thromboembolism J. Thromb. Haemost. 12 2014 1116 1120
17. N. van Es, M. Coppens, S. Schulman, S. Middeldorp, and H.R. Buller Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials Blood 124 2014 1968 1975
18. T.B. Larsen, P.B. Nielsen, F. Skjoth, L.H. Rasmussen, and G.Y. Lip Non-vitamin k antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes PLoS One 9 2014 e114445
19. C. Ay, and I. Pabinger Treatment and secondary prevention of venous thromboembolism in cancer patients. Current strategies and new therapeutic options Hamostaseologie 32 2012 139 144
20. E.J. Mills, K. Thorlund, and J.P. Ioannidis Demystifying trial networks and network meta-analysis BMJ 346 2013 f2914
21. S. Schulman, and C. Kearon Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J. Thromb. Haemost. 3 2005 692 694
22. A.Y. Lee, P.W. Kamphuisen, G. Meyer, R. Bauersachs, M.S. Janas, M.F. Jarner, and A.A. Khorana A Randomized Trial of Long-Term Tinzaparin, a Low Molecular Weight Heparin (LMWH), Versus Warfarin for Treatment of Acute Venous Thromboembolism (VTE) in Cancer Patients - the CATCH Study 2014
23. G. Agnelli, H.R. Büller, A. Cohen, M. Curto, A.S. Gallus, R. Pak, G.E. Raskob, J.I. Weitz, and T. Yamabe Abstract PP5527: Apixaban for the treatment of venous thromboembolism in cancer patients: data from the AMPLIFY trial Eur. Heart J. 2014 994
24. S. Schulman, H. Eriksson, S.Z. Goldhaber, S. Kakkar, C. Kearon, S.M. Schellong, M. Feuring, N. Peter, and J. Friedman Influence Of Active Cancer On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II 2013
25. G.E. Raskob, H.R. Büller, P. Angchaisuksiri, D. Oh, Z. Boda, R.M. Lyons, J.I. Weitz, G. Zhang, H.J. Lanz, and M. Mercuri Edoxaban For Long-Term Treatment Of Venous Thromboembolism In Cancer Patients 2013
26. A. Chaimani, J.P. Higgins, D. Mavridis, P. Spyridonos, and G. Salanti Graphical tools for network meta-analysis in STATA PLoS One 8 2013 e76654
27. I.R. White Multivariate random-effects meta-regression: Updates to mvmeta Stata J. 11 2011 255 270
28. S.R. Deitcher, C.M. Kessler, G. Merli, J.R. Rigas, R.M. Lyons, and J. Fareed Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period Clin. Appl. Thromb. Hemost. 12 2006 389 396
29. G. Meyer, Z. Marjanovic, J. Valcke, B. Lorcerie, Y. Gruel, P. Solal-Celigny, and et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study Arch. Intern. Med. 162 2002 1729 1735
30. A.Y. Lee, M.N. Levine, R.I. Baker, C. Bowden, A.K. Kakkar, M. Prins, and et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer N. Engl. J. Med. 349 2003 146 153
31. R.D. Hull, G.F. Pineo, R.F. Brant, A.F. Mah, N. Burke, R. Dear, and et al. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms Am. J. Med. 120 2007 72 82
32. A. Romera, M.A. Cairols, R. Vila-Coll, X. Marti, E. Colome, A. Bonell, and et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis Eur. J. Vasc. Endovasc. Surg. 37 2009 349 356
33. M.H. Prins, A. Lensing, T.A. Brighton, R.M. Lyons, J. Rehm, M. Trajanovic, B.L. Davidson, J. Beyer-Westendorf, F.A. Pap, S.D. Berkowitz, A.T. Cohen, M.J. Kovacs, P.S. Wells, and P. Prandoni Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials Lancet Haematol. 1 2014 e37 e46